Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis.
Tae Jung KimJi Sung LeeJae Sun YoonMi Sun OhJi-Woo KimSoo-Hyun ParkKeun Hwa JungHyun Young KimJee-Hyun KwonHye-Yeon ChoiHahn Young KimKyung Yoon EahSang Won HanHyung-Geun OhYoung-Jae KimByoung-Soo ShinChang Hun KimChi Kyung KimJong-Moo ParkKyung Bok LeeTai Hwan ParkJun LeeMan-Seok ParkJay Chol ChoiChulho KimDong-Ick ShinSoo Joo LeeDong-Eog KimJae-Kwan ChaEung-Gyu KimKyung-Ho YuKeun-Sik HongYoung-Seok LeeJu-Hun LeeSung Il SohnHee-Joon BaeYoung-Bae LeeJun Hong LeeJoung-Ho RhaByung-Chul LeeDae-Il ChangSang-Bae KoByung-Woo YoonPublished in: International journal of stroke : official journal of the International Stroke Society (2023)
This study demonstrated that OAC monotherapy was associated with lower risks of composite outcome and death in patients at 1 year after ischemic stroke due to AF and atherosclerotic stenosis. In addition, the combination of an antiplatelet and OAC had a high risk of major bleeding.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- cardiovascular disease
- randomized controlled trial
- human health
- open label
- risk assessment
- clinical trial
- combination therapy
- climate change
- venous thromboembolism
- study protocol